WithdrawnPhase 2

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19

Stopped: Difficulty in Recruitment

China0Started 2023-04-01

Plain-language summary

To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The age ranges from 18 to 85 (inclusive), regardless of gender.
✓. Patients with Confirmed SARS-CoV-2 infection, according to the consensus of the Chinese diagnostic criteria for COVID-19 (Tentative tenth Edition).
✓. Patients with symptoms of long COVID-19 3 months from the onset of COVID-19, lasting for at least 2 months, and the symptoms cannot be explained by other diseases.
✓. Be expected to live longer than 1 year.
✓. Volunteer to participate in this clinical study and sign the written informed consent.

✕. Those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation.
✕. T lymphocyte abnormality, HIV positive.
✕. Highly allergic or have a history of severe allergy.
✕. Pregnant and lactating women.
✕. Patients with severe autoimmune disease history;
✕. Patients with uncontrolled chronic diseases or serious complications;
✕. Patients with malignant tumors;
✕. Patients with pulmonary embolism, acute coronary syndrome, cerebral embolism or at high risk of thromboembolism;

Six min walking distances

Timeframe: Changes from baseline index at Day 30, Day 60, Day 90 and Day 180

Lung function

Timeframe: Changes from the baseline index at Day 30, Day 60, Day 90 and Day 180

NCT IDNCT05719012

SponsorShanghai East Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-01